Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis

EJNMMI Research

Table 1 Characteristics of patients, n = 27

		Patient characteristics
Age		48.1 ± 10.0 years
Gender (male)		17 (63.0%)
Caucasian		24 (88.9%)
Smoking history	Current	4 (14.8%)
	Former	13 (48.1%)
	Non-smoker	10 (37.0%)
Scadding stages at initiation of infliximab	I	1 (3.7%)^a
	II	5 (18.5%)
	III	4 (14.8%)
	IV	17 (63%)

^aTreatment indication for infliximab in this patient was severe obstructive pulmonary function caused by endobronchial stenosing